Engineered immune cells take on stubborn arthritis in early trial
Disease control
Recruiting now
This early-stage study tests a new treatment called ADI-001 for people with rheumatoid arthritis that hasn't improved with standard therapies. ADI-001 uses specially engineered immune cells from a donor to target and destroy faulty immune cells that attack the joints. The main go…
Phase: PHASE1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:00 UTC